Petros Pharmaceuticals Inc (PTPI) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Petros Pharmaceuticals Inc (PTPI) has a cash flow conversion efficiency ratio of 0.156x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.49 Million) by net assets ($-9.58 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See defensive interval ratio of Petros Pharmaceuticals Inc to measure how many days the company can operate on defensive assets alone.
Petros Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how Petros Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Petros Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Petros Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
BOOSH PLANT-BASED BRANDS
F:77I
|
N/A |
|
Wishbone Gold Plc
LSE:WSBN
|
-0.187x |
|
Marechale Capital Plc
LSE:MAC
|
-0.059x |
|
OCA Acquisition Corp
NASDAQ:OCAXU
|
-0.003x |
|
Global Lights Acquisition Corp Unit
NASDAQ:GLACU
|
-0.003x |
|
Renalytix AI plc
LSE:RENX
|
4.746x |
|
INSURAGUEST TECHN. INC.
F:4JG
|
0.216x |
|
Altona Rare Earths PLC
LSE:REE
|
-0.494x |
Annual Cash Flow Conversion Efficiency for Petros Pharmaceuticals Inc (2018–2024)
The table below shows the annual cash flow conversion efficiency of Petros Pharmaceuticals Inc from 2018 to 2024. For the full company profile with market capitalisation and key ratios, see Petros Pharmaceuticals Inc market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-7.47 Million | $-2.60 Million | 0.349x | +157.04% |
| 2023-12-31 | $12.48 Million | $-7.63 Million | -0.611x | +20.24% |
| 2022-12-31 | $16.70 Million | $-12.80 Million | -0.766x | -129.59% |
| 2021-12-31 | $35.54 Million | $-11.86 Million | -0.334x | +61.91% |
| 2020-12-31 | $17.47 Million | $-15.31 Million | -0.876x | -377.43% |
| 2019-12-31 | $8.02 Million | $2.53 Million | 0.316x | +106.62% |
| 2018-12-31 | $-1.68 Million | $8.02 Million | -4.771x | -- |
About Petros Pharmaceuticals Inc
Petros Pharmaceuticals, Inc., a healthcare technology company, focuses on developing and licensing proprietary SaaS platform and Software as a medical device web application designed to assist pharmaceutical companies. The company is based in New York, New York.